Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

20 May 2003 : Case report  

Efficacy of recombinant interferon alfa-2B (Realdiron)and Ribavirin (Rebetol)in combined therapy of different chronic hepatitis C (CHC)patients groups

D. Speiciene, A. Irnius, B. Titova, J. Jakutiene, J. Naraskeviciene, V. Liakina

Med Sci Monit 2003; 9(2): 16- :: ID: 15275

Abstract

Background:To compare the efficacy of combined treatment with recombinant Interferon alfa-2B (Realdiron,BIOTECHNA, VILNIUS)(IFN)and Ribavirin (Rebetol,Schering-Plough)(RBV)in different CHC patients (pts)groups:naive (N), relapsers (R)and non-responders (NR). Material/Methods:Overall 104 pts:67/64.4%with CHC and 37/35.6%with compensated liver cirrhosis (LC)(60/58%males and 44/42%females;age 24 –76 yr)were treated with IFN and RBV:gr.1 –9/8.7%N pts,gr.2 –22/21.2%R and gr.3 – 74/71.1%NR.Liver biopsy was carried out in 95/91.3%pts.LC (Child A and B)was diagnosed in 37/35.6%pts.IFN was given at a dose 3 –6 MU thrice a week with the induction dose 6MU daily for 2 weeks and RBV –800 –1200 mg twice daily (adjusted to the body weight)for 24 weeks.Six pts discontinued therapy because of the side effects.Results:Biochemical (BETR)and virological end of treatment response (VETR) were achieved overall in 52/50.0%and 34/32.7%pts,respectively,while complete response (CETR)–in 28/26.9%.Results of treatment depended on pts groups:6/66.7%of N,17/77.3%and 13/59.1%of R,and 29/39.7%and15/20.5%of NR showed BETR and VETR, respectively.During 6 months follow up some pts relapsed,so complete sustained response (CSR)(i.e.biochemical/SBR and virological/SVR)was found overall in 25/24%pts only and significantly varied in different pts groups:6/66.7%N pts,10/45.5%R and only 9/12.3%NR achieved CSR.Just 2/5.4%and 1/2.7%of R with LC achieved SBR and SVR,while CHC pts showed better results: CSR was found in – 24/35.8%pts.None of NR with LC and 9/21.4%with CHC showed SBR or SVR. Conclusions: Highest efficacy of combined therapy was achieved in relapses and naive pts,while virological and biochemical response of non-responders as well as pts with LC were significantly lower.

Keywords:

0 Comments

Editorial

04 June 2022 : Editorial  

Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?

Nahum Mendez-Sanchez, Shreya C. Pal
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

DOI: 10.12659/MSM.937371

Med Sci Monit 2022; 28:e937371

In Press

27 Jun 2022 : Clinical Research  

Automatic Identification of Depression Using Facial Images with Deep Convolutional Neural Network

Med Sci Monit In Press; DOI: 10.12659/MSM.936409  

23 Jun 2022 : Clinical Research  

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...

Med Sci Monit In Press; DOI: 10.12659/MSM.936706  

22 Jun 2022 : Clinical Research  

A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...

Med Sci Monit In Press; DOI: 10.12659/MSM.937316  

21 Jun 2022 : Clinical Research  

Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary Pancreatitis

Med Sci Monit In Press; DOI: 10.12659/MSM.937016  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750